Transgene is designing and developing next-generation immunotherapeutics against cancer
Innovative technologies
Push the boundaries of immunotherapy
Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network.
Discover our two therapeutic approaches
Discover our technologies
One patient, one cancer, one vaccine
With myvac®, Transgene enters the field of individualized immunotherapies with a unique virus-based immunotherapy platform.
myvac® video Discover myvac®
Watch Alessandro Riva presenting first clinical benefits of neoantigen cancer vaccine, TG4050, in head & neck cancer at AACR 2024
A new generation of products
These innovative multifunctional OVs are able to modulate the tumor micro-environment to better attack cancer.
invir.IO® en image Discover invir.IO®
TG4001
A therapeutic vaccine in Phase II
TG4001 targets HPV-induced anogenital cancers.
More information
Transgene et NEC Present Proof of Principle Data for TG4050 in Head & Neck Cancer
AACR 2024
Donwload Press release (PDF)
Interview of Alessandro Riva
Donwload the Poster (PDF)
–> article Home actus
Press releases
- April 24, 2024 - Availability of of Preparatory Documents for the Combined General Meeting of May 15, 2024
- April 11, 2024 - Availability of Transgene’s 2023 Universal Registration Document
- April 9, 2024 - Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
- March 27, 2024 - Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
Last publications
- April 9, 2024 - Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers
- August 29, 2023 - Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers
- May 26, 2023 - Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma
- May 26, 2023 - Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers
- April 16, 2023 - TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses
- September 11, 2022 - Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
- January 19, 2022 - Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors
- June 22, 2020 - Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
